Streetbeat News

Earnings

AAPL

AMD

EPI

EWW

GME

NVDA

QQQ

SPY

USO

India's stock market hits a lifetime high on exit polls predicting a landslide victory for Modi's BJP, while Mexico's peso and stocks fall on election results. AI advancements are announced by NVIDIA and AMD. Positive money flows are seen in major tech stocks and ETFs, while oil prices fall due to OPEC+ production changes.

Portfolio Pulse from The Arora Report

June 03, 2024 | 4:44 pm

HCSG

Healthcare Services Group, Inc. (NASDAQ:HCSG) announced a Q2 non-cash charge of ~$0.20 per share due to LaVie Care Centers' Chapter 11 bankruptcy filing. HCSG expects no disruption in postpetition payments and maintains its Q2 and 2024 adjusted cash flow expectations.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 4:37 pm

GILD

RCUS

Gilead Sciences and Arcus Biosciences released positive data from their Phase 2 EDGE-Gastric and ARC-9 studies, showing promising results in gastric and colorectal cancers. Despite recent setbacks in bladder cancer studies, these new findings could bolster investor confidence.

Portfolio Pulse from Vandana Singh

June 03, 2024 | 4:35 pm

FCEL

FuelCell Energy, Inc. (NASDAQ:FCEL) shares are trading higher, up more than 12% over the past five days. The company announced a significant agreement with Gyeonggi Green Energy Co., Ltd. to supply 42 upgraded fuel cell modules and a seven-year service agreement, expected to generate $160 million in revenue. Additionally, 22.63% of available shares are being sold short, which can lead to large price movements. FuelCell Energy is set to report its second-quarter financial results on June 10, with analysts expecting losses of 8 cents per share and quarterly revenue of $21.351 million. The stock has an average 1-year price target of $1.75, indicating a potential upside of 79.4%.

Portfolio Pulse from Erica Kollmann

June 03, 2024 | 4:31 pm

AMC

GME

Jim Cramer advises investors to take profits as shares of GameStop (GME) and AMC Entertainment (AMC) surge. Cramer warns that GameStop's business is declining and AMC's business is in a worse state, with repeated shareholder dilution. Keith Gill's large position in GameStop has sparked the rally.

Portfolio Pulse from Adam Eckert

June 03, 2024 | 4:29 pm

BTCUSD

ETHUSD

Analyst Ted provides a positive outlook for Bitcoin and Ethereum, citing slowing inflation and upcoming employment data as key factors. Bitcoin's weekly range is projected between $63,300 and $72,200, with critical support at $66,000. Ethereum's range is between $3,440 and $4,110. The market focus is on the Fed meeting and employment data, which could influence risk assets.

Portfolio Pulse from Khyathi Dalal

June 03, 2024 | 4:12 pm

JNJ

Johnson & Johnson announced long-term data from the Phase 1/2 MajesTEC-1 study of Tecvayli, showing sustained deep and durable responses in patients with relapsed or refractory multiple myeloma. The study demonstrated a 63% overall response rate and a 46% complete response rate. Safety profiles remained consistent, and the use of tocilizumab reduced the incidence of cytokine release syndrome.

Portfolio Pulse from Vandana Singh

June 03, 2024 | 4:01 pm

BPTH

CAMP

CNSP

GME

LSCC

MBOT

U.S. stocks traded mostly lower with the Dow Jones falling over 200 points. Crude oil prices dropped by 3.4%, and U.S. construction spending fell by 0.1% in April. Notable stock movements include Bio-Path Holdings, Microbot Medical, and GameStop rising significantly, while CalAmp Corp, Lattice Semiconductor, and CNS Pharmaceuticals saw substantial declines.

Portfolio Pulse from Avi Kapoor

June 03, 2024 | 4:00 pm

ARWR

Arrowhead Pharmaceuticals shares are trading higher following positive topline results from the Phase 3 PALISADE study of plozasiran in patients with familial chylomicronemia syndrome. The company also met all key secondary endpoints.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:46 pm

NTLA

Intellia Therapeutics (NASDAQ:NTLA) shares surged 11.2% after the company announced promising long-term data from its Phase 1 study of NTLA-2002, a CRISPR-based gene-editing therapy for hereditary angioedema (HAE). The single-dose treatment showed a 98% reduction in monthly HAE attacks and was well-tolerated with no severe side effects.

Portfolio Pulse from Dylan Berman

June 03, 2024 | 3:33 pm